文献速递肾移植

肾移植后成人及儿童移植后淋巴增殖性疾病发病率与预测因素:注册研究

Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

基于澳大利亚和新西兰透析与移植登记(1963-2015)的23 477例肾移植受者,采用竞争风险模型计算PTLD累积发病率并与年龄匹配人群比较。成人25年累积发病率为3.3%,儿童为3.6%;儿童淋巴瘤风险较一般人群增加30倍(SIR 29.5),高于成人(SIR 8.4)。EBV阴性、糖尿病、非抗CD25单抗诱导及移植年份与PTLD独立相关,2000年后发病率下降。

要点

  • 儿童肾移植受者淋巴瘤风险较同龄一般人群增加30倍,高于成人。
  • EBV阴性受者、糖尿病、非抗CD25单抗诱导的PTLD风险显著增加。
  • 2000年后移植年份与PTLD风险降低独立相关,发病率呈下降趋势。

核心结论

  • 成人与儿童肾移植受者PTLD累积发病率相似,但儿童淋巴瘤相对风险更高。
  • EBV阴性、糖尿病、非抗CD25单抗诱导及较早移植年份与PTLD风险增加独立相关。

研究设计与样本

  • 基于澳大利亚和新西兰透析与移植登记(1963-2015)的注册研究,纳入23 477例肾移植受者(92%成人,60%男性)。
  • 采用竞争风险死亡模型计算PTLD累积发病率,以标准化发病率比(SIR)与年龄匹配人群比较。
  • 采用Cox比例风险回归评估PTLD风险因素。

主要发现

  • 共505例发生PTLD,其中50例(10%)为儿童受者。
  • 成人25年累积PTLD发病率为3.3%(95%CI 2.9-3.6),儿童为3.6%(95%CI 2.7-4.8)。
  • 儿童淋巴瘤SIR为29.5(95%CI 21.9-38.8),成人SIR为8.4(95%CI 7.7-9.2)。
  • EBV阴性受者aHR 3.33(95%CI 2.21-5.01,P<0.001);糖尿病aHR 3.49(95%CI 2.26-5.38,P<0.001)。
  • 非抗CD25单抗诱导aHR 2.07(95%CI 1.16-3.70,P=0.01);2000年后每一年aHR 0.93(95%CI 0.88-0.99,P=0.02)。

临床怎么用

  • 对EBV阴性肾移植受者应加强PTLD监测与预防策略。
  • 合并糖尿病的受者需警惕PTLD风险升高。
  • 选择诱导方案时需权衡非抗CD25单抗诱导相关的PTLD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differences in the epidemiology of post-transplant lymphoproliferative disease (PTLD) between adult and paediatric kidney transplant recipients remain unclear. METHODS: Using the Australian and New Zealand Dialysis and Transplant Registry (1963-2015), the cumulative incidences of PTLD in children (age <20 years) and adults were calculated using a competing risk of death model and compared with age-matched population-based data using standardized incidence ratios (SIRs). Risk factors for PTLD were assessed using Cox proportional hazards regression. RESULTS: Among 23 477 patients (92% adult, 60% male), 505 developed PTLD, with 50 (10%) occurring in childhood recipients. The 25-year cumulative incidence of PTLD was 3.3% [95% confidence interval (CI) 2.9-3.6] for adult recipients and 3.6% (95% CI 2.7-4.8) for childhood recipients. Childhood recipients had a 30-fold increased risk of lymphoma compared with the age-matched general population [SIR 29.5 (95% CI 21.9-38.8)], higher than adult recipients [SIR 8.4 (95% CI 7.7-9.2)]. Epstein-Barr virus (EBV)-negative recipient serology [adjusted hazard ratio (aHR) 3.33 (95% CI 2.21-5.01), P < 0.001], year of transplantation [aHR 0.93 for each year after the year 2000 (95% CI 0.88-0.99), P = 0.02], induction with an agent other than anti-CD25 monoclonal antibody [aHR 2.07 (95% CI 1.16-3.70), P = 0.01] and having diabetes [aHR 3.49 (95% CI 2.26-5.38), P < 0.001] were independently associated with PTLD. CONCLUSIONS: Lymphoma occurs at similar rates in adult and paediatric recipients, but has been decreasing since the year 2000. EBV-negative patients and those with diabetes or induction agent other than anti-CD25 monoclonal antibody are at substantially increased risk of PTLD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Francis A, Johnson DW, Teixeira-Pinto A, et al. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. Nephrol Dial Transplant. 2018. PMID: 29342279. doi:10.1093/ndt/gfx356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。